Fondaparinux — Membership Pricing

Other medications in Blood & Hematology

• Dalteparin
• Deferasirox
• Deferoxamine

About Fondaparinux

Fondaparinux is a critical anticoagulant medication often prescribed to prevent and treat dangerous blood clots like deep vein thrombosis (DVT) and pulmonary embolism (PE). Understanding its role is crucial for patient health. At TheDrugClub, we believe in making essential medications like fondaparinux more accessible and affordable, helping you manage your health without the added financial strain.

Fondaparinux is a synthetic anticoagulant, meaning it's designed to prevent blood from clotting. It plays a vital role in modern medicine, primarily focusing on conditions where blood clots pose a significant risk to patient health.

What Fondaparinux Treats

This medication is primarily prescribed for the prevention and treatment of deep vein thrombosis (DVT), a condition where blood clots form in deep veins, usually in the legs. It's also used to treat pulmonary embolism (PE), a life-threatening condition occurring when a DVT clot travels to the lungs. Furthermore, fondaparinux is commonly used to prevent DVT in patients undergoing major orthopedic surgeries, such as hip fracture surgery, knee replacement surgery, or hip replacement surgery, where the risk of clot formation is particularly high due to immobility and tissue trauma.

How Fondaparinux Works

Fondaparinux works by selectively inhibiting Factor Xa, a crucial enzyme in the coagulation cascade (the series of steps that lead to blood clot formation). By

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Fondaparinux is approved for (FDA label)

Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. ( 1.1 ) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. ( 1.2 , 1.3 ) 1.1 Prophylaxis of Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip replacement surgery; in patients undergoing knee replacement surgery; in patients undergoing abdominal surgery who are at risk for thromboembolic complications. 1.2 Treatment of Acute Deep Vein Thrombosis Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. 1.3 Treatment of Acute Pulmonary Embolism Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.

Source: Read the full FDA label on DailyMed. Label effective date: October 28, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Fondaparinux (FDA label)

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants a history of traumatic or repeated epidural or spinal puncture a history of spinal deformity or spinal surgery Optimal timing between the administration of fondaparinux sodium and neuraxial procedures is not known. Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. [See Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7 ).] WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fondaparinux (FDA label)

Single-dose, prefilled syringes containing either 2.5 mg, 5 mg, 7.5 mg, or 10 mg of fondaparinux sodium. ( 3 ) Single-dose, prefilled syringes containing 2.5 mg, 5 mg, 7.5 mg, or 10 mg of fondaparinux sodium. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fondaparinux (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Spinal or epidural hematomas [see Warnings and Precautions ( 5.1 )] . Hemorrhage [see Warnings and Precautions ( 5.2 )] . Renal impairment and bleeding risk [see Warnings and Precautions ( 5.3 )] . Body weight <50 Kg and bleeding risk [see Warnings and Precautions ( 5.4 )] . Thrombocytopenia [see Warnings and Precautions ( 5.5 )] . The most clinically significant adverse reactions associated with the use of fondaparinux sodium are bleeding complications. ( 6.1 ) Mild local irritation (injection site bleeding, rash and pruritus) may occur following subcutaneous injection. ( 6.2 ) Anemia, insomnia, increased wound drainage, hypokalemia, dizziness,hypotension, confusion, bullous eruption, hematoma, post-operative hemorrhage, and purpura may occur. ( 6.4 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA), Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fondaparinux (FDA label)

Fondaparinux sodium injection is contraindicated in the following conditions:( 4 ) Severe renal impairment (creatinine clearance [CrCl] <30 mL/min). [See Warnings and Precautions ( 5.3 ) and Use in Specific Populations ( 8.6 ).] Active major bleeding. Bacterial endocarditis. Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium. Body weight <50 kg (venous thromboembolism [VTE] prophylaxis only) [see Warnings and Precautions ( 5.4 )]. History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/ anaphylactic reactions) to fondaparinux sodium injection. Fondaparinux sodium injection is contraindicated in the following conditions: ( 4 ) Severe renal impairment (creatinine clearance <30 mL/min) in prophylaxis or treatment of venous thromboembolism. Active major bleeding. Bacterial endocarditis. Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium. Body weight <50 kg (venous thromboembolism prophylaxis only).

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fondaparinux (FDA label)

Spinal or epidural hematomas, which may result in long-term or permanent paralysis, can occur. ( 5.1 ) Patient taking fondaparinux sodium with risk factors for bleeding are at increased risk of hemorrhage. ( 5.2 ) Bleeding risk is increased in renal impairment and in patients with low body weight <50 kg. ( 5.3 , 5.4 ) Thrombocytopenia can occur with administration of fondaparinux sodium. ( 5.5 ) Periodic routine complete blood counts (including platelet counts), serum creatinine level, and stool occult blood tests are recommended ( 5.6 ) The packaging (needle guard) contains dry natural rubber and may cause allergic reactions in latex sensitive individuals ( 5.7 ) 5.1 Neuraxial Anesthesia and Post-operative Indwelling Epidural Catheter Use Spinal or epidural hematomas, which may result in long-term or permanent paralysis, can occur with the use of anticoagulants and neuraxial (spinal/epidural) anesthesia or spinal puncture.

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fondaparinux (FDA label)

In clinical studies performed with fondaparinux sodium, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium. In addition, fondaparinux sodium neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state. Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of therapy with fondaparinux sodium unless these agents are essential.

Source: FDA prescribing information (DailyMed). Set ID: dffbf7c9-495e-4a33-ac76-57b52f014fc2. SPL document ID: 4234bd9e-7f61-2cb0-e063-6294a90a4e14. Label effective date: October 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.